INMB · Inmune Bio, Inc.
$2.17
+0.09 (+4.33%)
At close · Aug 14
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Given the Company's projected operating requirements and its existing cash and cash equivalents, the Company is projecting insufficient liquidity to sustain its operations through one year following the date that the financial statements are issued. These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. Because management's plans have not yet been finalized and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$60.23M
Shares
27.75M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$50K
+257.1%
FY2025
Net Income
-$45.93M
-9.2%
FY2025
Operating Margin
-94766%
+209769.7pp
FY2025
Diluted EPS
-$1.86
+11.8%
FY2025
Operating Cash Flow
-$22.58M
+32.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| — | $50K | $14K | $155K | $374K | $181K | $11K | — | $0 | $0 | |
| — | $17K | — | — | — | — | — | — | — | — | |
| $16.66M | $20.66M | $33.17M | $20.27M | $17.07M | $20.54M | $5.92M | $3.28M | $3.35M | $435.36K | |
| $10.14M | $10.26M | $9.48M | $9.62M | $9.26M | $8.79M | $6.32M | $6.02M | $9.09M | $546.12K | |
| $20.2M | $47.43M | $42.65M | $29.9M | $26.33M | $29.33M | $12.24M | $7.76M | $12.44M | $981.48K | |
| -$20.2M | -$47.38M | -$42.64M | -$29.74M | -$25.95M | -$29.15M | -$12.23M | -$7.76M | -$12.44M | -$981.48K | |
| — | -94766% | -304535.71% | -19187.74% | -6938.77% | -16106.63% | -111163.64% | — | — | — | |
| $0 | — | $357K | $2.28M | $2.01M | — | — | — | — | — | |
| $1.78M | $1.45M | $553K | -$267K | -$1.35M | -$1.19M | $129K | $77.69K | — | $149.99K | |
| — | $45.93M | $42.08M | $30.01M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $0 | $0 | |
| -$18.42M | -$45.93M | -$42.08M | -$30.01M | -$27.3M | -$30.34M | -$12.1M | -$7.68M | -$12.44M | -$831.49K | |
| — | -91866% | -300585.71% | -19360% | -7299.2% | -16762.43% | -109990.91% | — | — | — | |
| -$18.48M | -$46.1M | -$41.86M | -$30.11M | -$28M | -$30.35M | -$12.08M | -$7.69M | -$12.47M | -$796.6K | |
| USD/shares | — | -$1.86 | -$2.11 | -$1.67 | -$1.52 | -$1.88 | — | — | — | — |
| USD/shares | — | -$1.86 | -$2.11 | -$1.67 | -$1.52 | -$1.88 | — | — | — | — |
| shares | — | 24.76M | 19.94M | 17.98M | 17.93M | 16.13M | 11.99M | 10.27M | 8.68M | 6.56M |
| shares | — | 24.76M | 19.94M | 17.98M | 17.93M | 16.13M | 11.99M | 10.27M | 8.68M | 6.56M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.40×
EV/EBIT
—
Peer median 11.89×
P/E (TTM)
—
Peer median 8.79×
Peer medians compare against the 303 similar-size Biotechnology companies (of 545 listed).
Valuation over time computed as of each quarter's filing date
Key facts
CIK
1711754
CUSIP
45782T105
13F (30d)
78 filings
78 filers
Visit website
Investor relations